OR WAIT null SECS
June 21, 2018
The contract development and manufacturing company has received an additional approval from Health Canada to manufacture monoclonal antibody drug substance at its first plant in Icheon, South Korea.
June 19, 2018
WuXi STA supported the development of hepatitis drug through marketing authorization holder pilot program.
June 13, 2018
Cambrex expands its generic API research and development capabilities at its Milan, Italy site.
June 06, 2018
Under the contract, AMRI will focus on the development and manufacture of APIs and drug product for Phase I clinical studies.
June 02, 2018
From separation systems to reactor technology, new tools are increasing the feasibility of continuous API production.
June 01, 2018
Cambrex invests $5 million in new laboratory expansion at its Karlskoga, Sweden facility.
May 30, 2018
GE Healthcare and the Centre for Commercialization of Regenerative Medicine (CCRM) will support scale-up efforts by DiscGenics for a new cell therapy intended to treat back pain.
May 29, 2018
This marks the third FDA approval for the company’s second biomanufacturing plant in Incheon, Korea.
May 16, 2018
Cambrex Corporation has announced facility, equipment, and instrument upgrades at its High Point, NC facility and updated progress on expansions in Cedar City, IA.
April 24, 2018
Porton will use biocatalyst technologies from Codexis to accelerate API development for clients.